These findings show that AI applied to routine histopathology can serve as a practical and scalable tool for guiding chemotherapy decisions in hormone receptor-positive, HER2-negative, early breast cancer. This approach has the potential to reduce unnecessary chemotherapy and broaden access to precision oncology, particularly in resource-limited settings where genomic testing remains unavailable or unaffordable.
[Articles] Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study
The Lancet Oncology | | Gil Shamai, Shachar Cohen, Yoav Binenbaum, Edmond Sabo, Alexandra Cretu, Chen Mayer, Iris Barshack, Tal Goldman, Gil Bar-Sela, António Polónia, Dezheng Huo, Alexander T Pearson, Frederick M Howard, Joseph A Sparano, Ron Kimmel, Dvir Aran
Topics: breast-cancer, chemotherapy, new-technology, research